BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:ALTO-300 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of ALTO-300\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05922878-807@assetmemo.bio
DTSTAMP:20261121T004956Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:ALTO-300: Phase 2 readout est. (NCT05922878)
DESCRIPTION:ALTO-300\, phase 2\, Major Depressive Disorder.\nStudy: Study o
 f ALTO-300 in MDD\nEstimated primary completion: December 2026. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/alto-300#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT05922878
URL:https://assetmemo.bio/drug/alto-300#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
